Companies to market new drug-dispensing solution for pharmaceutical testing.
The Tecan Group (SIX Swiss Exchange: TECN) and HP (NYSE: HPQ) today announced that they have entered into an agreement to commercialize products based on HP’s high-performance inkjet dispensing technology for pharmaceutical drug discovery. The new dispensing technology intended for use in research is designed to enable biopharma researchers to accelerate and improve the evaluation of novel research drugs. Under the agreement, Tecan will provide exclusive sales, marketing, service and support through its Life Sciences Business for the instruments and consumables. Products will be sold under the HP brand. Tecan will begin marketing the products across the United States and Europe. Products are expected to be commercially available later this year. The new high-performance dispensing products commercialized by Tecan and HP will be used in research to speed the evaluation of how potential drug compounds impact biological agents at very low concentrations. This new capability can benefit research by significantly improving accuracy when evaluating drug effectiveness, testing drug interactions and developing new drugs.
Thomas Bachmann, CEO of Tecan, said: “We are delighted to partner with HP to bring such an exciting dispensing technology to the biopharma research market. Part of Tecan’s strategy is to seek new, innovative, third-party products that enhance the broad product portfolio of our Life Sciences Business. This agreement allows us to offer our customers new products that simplify and improve the evaluation of drug potency. We see the alliance of HP’s industry-leading printing technology and Tecan’s market leadership in laboratory instruments and solutions as the perfect union to best serve our customers.”
Kathy Tobin, vice president and general manager of Specialty Printing Systems at HP, said: “HP continues to develop new applications where our inkjet technology can address current challenges and quickly bring new value to a variety of industries. HP and Tecan’s combined resources can help accelerate the drug discovery process, providing biopharmaceutical companies with even greater opportunity for drug innovation."
More information about the offering by Tecan and HP is available at www.tecan.com and www.hp.com/go/High-PerformanceDispensing.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2010, Tecan generated sales of CHF 371 million (USD 356 million; EUR 269 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).
HP creates new possibilities for technology to have a meaningful impact on people, businesses, governments and society. The world’s largest technology company, HP brings together a portfolio that spans printing, personal computing, software, services and IT infrastructure at the convergence of the cloud and connectivity, creating seamless, secure, context-aware experiences for a connected world. More information about HP (NYSE: HPQ) is available at www.hp.com.